Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization

Macular DiseasesRetinal Diseases

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles

Br J Ophthalmol

Vofo BN, Beykin G, Levy J, Chowers I

doi: 10.1136/bjophthalmol-2021-319054

Cornea and Corneal Diseases

Long-term outcomes of penetrating keratoplasty for corneal complications of herpes zoster ophthalmicus

Br J Ophthalmol.

Tanaka TS, Hood CT, Kriegel MF, Niziol L, Soong HK

doi: 10.1136/bjophthalmol-

Macular Diseases

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration

Ophthalmology.

Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, Hunt A, Gillies MC, Barthelmes D; Fight Retinal Blindness! Study Group

doi: 10.1016/j.ophtha.

Uveitis

Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Ophthalmology.

Al-Janabi A, El Nokrashy A, Sharief L, Nagendran V, Lightman S, Tomkins-Netzer O

doi: 10.1016/j.ophtha.2019.08.031.

Cornea and Corneal Diseases

Treatment of neurotrophic keratopathy with minimally invasive corneal neurotisation: long-term clinical outcomes and evidence of corneal reinnervation

Br J Ophthalmol.

Catapano J, Fung SSM, Halliday W, Jobst C, Cheyne D, Ho ES, Zuker RM, Borschel GH, Ali A

doi: 10.1136/bjophthalmol-

Blindness and Vision ImpairmentLenses

Chronic Ocular Sequelae of Stevens-Johnson Syndrome in Children: Long-term Impact of Appropriate Therapy on Natural History of Disease

Am J Ophthalmol.

Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS

doi: 10.1016/

COMMENTED

Macular DiseasesRetinal Diseases

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ

doi: 10.1097/IAE.

Uveitis

Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study

Br J Ophthalmol.

Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, Dick AD

doi: 10.1136/bjophthalmol-

Macular Diseases

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Clin Exp Ophthalmol.

Spooner K, Fraser-Bell S, Hong T, Chang A

doi: 10.1111/ceo.13636.

Related content

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles

Long-term outcomes of penetrating keratoplasty for corneal complications of herpes zoster ophthalmicus

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration

Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Treatment of neurotrophic keratopathy with minimally invasive corneal neurotisation: long-term clinical outcomes and evidence of corneal reinnervation

Chronic Ocular Sequelae of Stevens-Johnson Syndrome in Children: Long-term Impact of Appropriate Therapy on Natural History of Disease

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab